INTRODUCTION
Acne vulgaris is a common, chronic skin disorder that affects
70% to 87% of the adolescent population.1-3 While acne occurs
mostly in pubescent teens, older individuals may also be
afflicted.4 Moreover, it has been reported that suffering from
acne may have psychological impact leading to anxiety, depression,
and suicide.5
Acne vulgaris is characterized by several abnormalities in
sebum production, follicular epithelial desquamation, bacterial
proliferation, and inflammation.6 Because acne is a multifactorial
disease, effective treatment may involve different
combination therapies to control the disease. Such combination
regimens are sometimes necessary to address the individual
needs of each patient, particularly in more severe cases.
The US FDA has approved several agents to treat acne vulgaris.
Adapalene, tazarotene, and tretinoin are topical
retinoids that exhibit safe profiles for the treatment of facial
acne. Local effects from the use of retinoids, especially prevalent
in the early course of treatment, include peeling, erythema,
dryness, burning, and itching; however, these effects
can be reduced by limiting exposure to sunlight, extreme
temperatures, and increasing use of moisturizers.7 Retinoids
in particular have played an important role in the treatment
of acne because they target the microcomedone—the primary
lesion of acne.
Therapies involving retinoids in combination with oral and/or
topical antibiotics have proven to be effective and safe for the
treatment of acne vulgaris. Previously published studies have
reported that the combination of a retinoid, such as adapalene
gel 0.1% or tazarotene gel 0.1%, with an oral antibiotic is
more effective in improving both inflammatory and noninflammatory
acne lesions as compared to monotherapy with an
antibiotic alone.8,9 Likewise, combination therapies with
these retinoids and topical antibiotics also result in more
beneficial effects compared to treatments with only the topical
antibiotic.10-12 Although studies have reported similar efficacious
results, differences in tolerability, safety, and patient
satisfaction may suggest that one combination treatment
regimen may exhibit more preferable outcomes than another.
Understanding these differences will help the treating physician
make appropriate choices for each individual patient.
Retinoids and Oral Antibiotics
Adapalene gel 0.1% and doxycycline
In a 12-week study, 467 patients with severe acne were randomized
to receive doxycycline (100 mg capsule) once daily
in the morning and either adapalene gel 0.1% or adapalene
gel vehicle once daily in the evening.8
Reductions in lesions were statistically in favor of the combination
regimen for both inflammatory (P=.02), and noninflammatory
(P<.001) lesions (Figure 1a). At the end of the
study, the percent of patients rated as success (clear or almost
clear) was significantly higher with adapalene gel 0.1% and